机会均等
动画
机会均等

Video

Accelerated First in Human Trial of a Promising SARS-CoV-2 Antiviral

October 27, 2021
The critical need for potent SARS-CoV-2 treatments has required acceleration of development timelines without compromising safety. Learn how one biotech company was able to administer the first human dose of a new antiviral just 23 days after first meeting with the CRO. Within nine weeks this promising new product was ready for Phase II testing, instead of the standard eight months for a similar study.